Sequence Analysis of the Fusion Protein Gene of Human Respiratory Syncytial Virus Circulating in China from 2003 to 2014

Jinhua Song, Huiling Wang, Teresa I. Ng, Aili Cui, Shuangli Zhu, Yanzhi Huang, Liwei Sun, Zifeng Yang, Deshan Yu, Pengbo Yu, Hong Zhang, Yan Zhang & Wenbo Xu

The human respiratory syncytial virus (HRSV) fusion (F) protein is important for HRSV infection, but few studies have examined the genetic diversity of the F gene from Chinese samples. In this study, a total of 330 HRSV F sequences collected from different regions of China between 2003 and 2014 were analyzed to understand their genetic characteristics. In addition, these sequences were compared with 1150 HRSV F sequences in Genbank from 18 other countries. In phylogenetic analysis, Chinese HRSV F sequences sorted into a number of clusters containing sequences from China as well as other countries. F sequences from different genotypes (as determined based on the G gene sequences) within a HRSV subgroup could be found in the same clusters in phylogenetic trees generated based on F gene sequences. Amino acid analysis showed that HRSV F sequences from China and other countries were highly conserved. Of interest, F protein sequences from all Chinese samples were completely conserved at the palivizumab binding site, thus predicting the susceptibility of these strains to this neutralizing antibody. In conclusion, HRSV F sequences from China between 2003 and 2014, similar to those from other countries, were highly conserved.

Human respiratory syncytial virus (HRSV) is one of the leading pathogens causing lower-respiratory tract infections in infants and young children worldwide. HRSV is a single-stranded, negative-sense RNA virus in the Pneumoviridae family. The attachment glycoprotein (G protein) and the fusion glycoprotein (F protein) are the two major glycoproteins on the HRSV surface. The G protein mediates the viral attachment to the host cells whereas the F protein mediates viral penetration and fusion of the infected cells. HRSV could be divided into two subgroups, subgroup A (HRSVA) and subgroup B (HRalVB), based on the antigenic characteristics and the reactivity with monoclonal antibodies. The HRSV G gene sequence is highly variable. Based on the sequences of the second hypervariable region of the G gene, HRSV strains from each subgroup are further classified into different genotypes. To date, 15 genotypes of HRSVA have been identified (GA1–7, NA1–4, ON1–2, SAA1, CBA) whereas 30 genotypes of HRalVB have been identified (GB1–4, BA1–14, BAc, SAB1–4, URU1–2, CB1(GB5), CBB, BA-CCA, BA-CCB and THB). According to the phylogenetic analysis of the G gene, the same predominant clades of HRSV circulated globally, and when different HRSV strains emerged, the distribution of the old clades could be changed.

The F protein is synthesized as a precursor F0 protein [574 amino acids (aa) in length]. When the F0 protein passes through the Golgi, it can be activated by the cleavage with a furin-like intracellular host protease at 2 sites.

1WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People’s Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People’s Republic of China. 2AbbVie, Inc, North Chicago, IL, USA. 3Jilin Children’s Medical Center, Children’s Hospital of Changchun, Changchun, People’s Republic of China. 4State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China. 5Gansu Provincial Centers for Disease Control and Prevention, Lanzhou, People’s Republic of China. 6Shaanxi Provincial Centers for Disease Control and Prevention, Xi’an, People’s Republic of China. 7Hunan Provincial Centers for Disease Control and Prevention, Changsha, People’s Republic of China. Correspondence and requests for materials should be addressed to Y.Z. (email: zhangyan9876543@163.com) or W.X. (email: wenbo_xu1@aliyun.com)
after amino acid residues 109 and 136 to generate three polypeptides: F1 (aa 137–574), F2 (aa 1–109) subunits and an intervening 27 amino acid peptide, pep27, (aa 110–136)16,17. The mature F protein is a homotrimer of the F1 and F2 subunits, and the F1 subunit is essential for the protein to cause membrane fusion. The F0 precursor contains 5 or 6 predicted N-linked glycosylation sites depending on the HRSV strain. After activation, 2 predicted N-linked glycosylation sites in F2, 1 predicted N-linked glycosylation site in F1 and 2–3 predicted N-linked glycosylation sites in the pep27 are left18,19.

The F protein has been identified as having at least two dominant conformations: the prefusion and postfusion forms20. The functional F protein trimer in the virion membrane is in a metastable, prefusion form. This prefusion F protein had a ’lollipop’ shape by electron microscopy21,22. In the prefusion form of the F1 protein, the fusion peptide at the N terminus of F1 is followed by 4 short α-helices connected by 3 non-helical peptides5. The structure of the postfusion F protein revealed a cone-shaped molecule, with a globular head and an extended stalk21. Three F2/F1 subunits that make up the trimeric molecule are tightly intertwined, with 3-fold symmetry that runs the length of the molecule. The globular head contains both the F2 and F1 subunits, as well as the cysteine-rich region. The stalk region is almost entirely helical, composed of the 6-helix bundle that is characteristic of the postfusion state of many type I viral fusion proteins21,22,23. The F protein is a target of virus-specific cytotoxic T lymphocytes (CTLs). Three related human HLA class I-restricted epitopes, HLA-A*01, HLA-A*0201 in HLA-A*01 transgenic mouse24, and 4 peptides of HRSV were found to bind to HLA-A*0201 in HLA-A2 transgenic mouse25. In addition, the F protein is a target of neutralizing antibody and vaccine development due to its high sequence conservation. To date, 6 antigenic sites have been identified in F protein: Ø, I, II, IV, V, and VI. Antigenic sites I, II and IV are present in the postfusion F conformations25,26, whereas antigenic site Ø is found only in the prefusion F conformation25. Antigen site Ø is at the apex of the prefusion trimer composed of an α-helix from F1 and a strand from F2; the other 5 antigenic sites are all within the F1 subunit22. Antigenic site I is located in the middle of cysteine rich region26, and antigenic sites IV, V, and VI overlap with the C terminus of the cysteine rich region26. Antigenic site II is the binding site of the neutralizing antibodies palivizumab and motavizumab, especially the domain spanning aa 262–27527,28. It has been shown that mutations at some of the residues in this domain resulted in resistance to palivizumab and/or motavizumab21,31,34,35.

The molecular epidemiology of HRSV in China has been studied quite extensively based on the G gene12,13, but information regarding the genetic diversity and sequence characteristics of the F gene from Chinese HRSV samples is limited. In the present study, the phylogenetic relationship and the sequence diversity of the F gene from Chinese HRSV samples collected from different regions in China were compared to those from other countries.

## Results

### Samples information.

A total of 181 (91 of HRSVA and 90 of HRSVB) HRSV samples were selected for F gene sequence analysis from over 700 HRSV-positive samples collected in 6 representative geographic regions of China between 2004 and 2014 (Supplementary Table S1). These samples were selected on the basis of their representation of the circulating strains in China [based on HRSV subgroup, genotype, genetic diversity (different clustering within a genotype in phylogenetic analysis using the sequences of the G gene), geographical region, and year of collection]12,13. In addition, all Chinese HRSV F gene sequences with full-length CDS that were available in GenBank as of October, 2016 (n = 149) (Supplementary Table S2) were downloaded and analyzed together with the 181 F sequences.

Therefore, a total of 330 Chinese HRSV F gene sequences collected from 2003 to 2014 were analyzed to determine their genetic diversity and sequence characteristics (Table 1 and Fig. 1). Moreover, 1150 HRSV F gene sequences (770 of HRSVA and 380 of HRSVB) with full-length CDS collected from 18 other countries between 1956 and 2014 were downloaded from GenBank for comparison study (Supplementary Table S2). More details of the sequences are available in Supplementary Tables S1, S2 and S3.

### Table 1. Distribution of Chinese HRSV samples by geographical region and year. Numbers shown are the sum of sequences collected in this study and those downloaded from GenBank; sequences collected in this study are shown within parentheses.

| Region/Province/City | Dongbei | Huabei | Huadong | Xibei | Zhongnan | Xinan |
|----------------------|---------|--------|---------|------|----------|------|
| Jilin                | —       | —      | 3(0)    | —    | —        | —    |
| Beijing              | —       | 6(6)   | —       | —    | —        | —    |
| Hebei                | 5(5)    | —      | —       | —    | 5(0)     | —    |
| Shanghai            | 26(26)  | —      | —       | —    | 2(2)     | 2(0) |
| Gansu                | 9(9)    | 1(1)   | 4(4)    | 5(5) | —        | 1(1) |
| Shaanxi              | 9(9)    | —      | 4(4)    | 5(5) | —        | 1(1) |
| Hunan                | —       | 1(1)   | —       | 8(8) | 3(3)     | 28(27)|
| Guangdong           | 7(7)    | —      | —       | —    | 5(5)     | 2(1) |
| Chongqing           | 8(8)    | —      | 4(4)    | 5(5) | 8(8)     | 1(0) |
| Total               | 28(28)  | 57(57) | 10(10)  | 5(4) | 13(13)   | 18(18)|

The F protein has been identified as having at least two dominant conformations: the prefusion and postfusion forms20. The functional F protein trimer in the virion membrane is in a metastable, prefusion form. This prefusion F protein had a ’lollipop’ shape by electron microscopy21,22. In the prefusion form of the F1 protein, the fusion peptide at the N terminus of F1 is followed by 4 short α-helices connected by 3 non-helical peptides5. The structure of the postfusion F protein revealed a cone-shaped molecule, with a globular head and an extended stalk21. Three F2/F1 subunits that make up the trimeric molecule are tightly intertwined, with 3-fold symmetry that runs the length of the molecule. The globular head contains both the F2 and F1 subunits, as well as the cysteine-rich region. The stalk region is almost entirely helical, composed of the 6-helix bundle that is characteristic of the postfusion state of many type I viral fusion proteins21,22,23. The F protein is a target of virus-specific cytotoxic T lymphocytes (CTLs). Three related human HLA class I-restricted epitopes, HLA-A*01, HLA-A*0201 in HLA-A*01 transgenic mouse24, and 4 peptides of HRSV were found to bind to HLA-A*0201 in HLA-A2 transgenic mouse25. In addition, the F protein is a target of neutralizing antibody and vaccine development due to its high sequence conservation. To date, 6 antigenic sites have been identified in F protein: Ø, I, II, IV, V, and VI. Antigenic sites I, II and IV are present in the postfusion F conformations25,26, whereas antigenic site Ø is found only in the prefusion F conformation25. Antigen site Ø is at the apex of the prefusion trimer composed of an α-helix from F1 and a strand from F2; the other 5 antigenic sites are all within the F1 subunit22. Antigenic site I is located in the middle of cysteine rich region26, and antigenic sites IV, V, and VI overlap with the C terminus of the cysteine rich region26. Antigenic site II is the binding site of the neutralizing antibodies palivizumab and motavizumab, especially the domain spanning aa 262–27527,28. It has been shown that mutations at some of the residues in this domain resulted in resistance to palivizumab and/or motavizumab21,31,34,35.

The molecular epidemiology of HRSV in China has been studied quite extensively based on the G gene12,13, but information regarding the genetic diversity and sequence characteristics of the F gene from Chinese HRSV samples is limited. In the present study, the phylogenetic relationship and the sequence diversity of the full-length coding DNA sequences (CDS) of the F genes from HRSV samples collected from different regions in China were compared to those from other countries.
Phylogenetic analysis of the F gene sequences. A total of 986 full-length CDS of the HRSV A F gene, including 216 sequences from China, sorted to 11 clusters in phylogenetic trees generated by neighbor joining method, A1-A11 (Fig. 2). Among these sequences, Chinese HRSVA sequences sorted to 5 of these clusters: A2, A5, A6, A7 and A11 (Fig. 2a).

Genotype GA5 sequences from the Huabei and Zhongnan regions of China from 2008–2009 and 2013, and genotype SAA1 and GA5 sequences from the USA, the Netherlands, South Africa sorted into cluster A2. Three sequences from the Huabei region of China from 2003 sorted to cluster A5 with 93% bootstrap value. Sequences from the Huabei, Zhongnan and Xinan regions of China from 2004, 2008–2012, which were classified as GA2, NA1 or NA4 genotypes sorted to cluster A7 with 97% bootstrap value. Cluster A11, the largest group, was populated by Chinese sequences classified as genotypes NA1, NA3, or ON1 from 2010 to 2014, and genotype GA2, NA1 or ON1 sequences from Vietnam, USA, Kenya, the Philippines, South Korea and other countries from 2006–2014 with 90% bootstrap value. Most Chinese HRSVA sequences were in phylogenetic clusters containing sequences from China as well as other countries, but not in clusters that were solely made up of Chinese sequences (Fig. 2 and Supplementary table S4a).

A total of 494 full-length CDS of the HRSV B F gene, including 114 sequences from China, sorted to 9 clusters in phylogenetic trees generated by neighbor joining method, B1-B9 (Fig. 3). Chinese HRSVB sequences distributed into clusters B1, B7, and B9 (Fig. 3a).

Genotype CB1 sequences from the Huabei, Dongbei, Zhongnan and Xinan regions of China from 2009–2012, and sequences from the USA from 1989–1995 (GB4 genotype), Kenya from 2002–2004 (SAB1 genotype) and South Africa from 1998–2001 (SAB4 genotype) sorted to cluster B7 with 73% bootstrap value. Three SAB4 sequences from the Huabei region of China from 2009, 1 sequence from Germany in 2008 and 3 genotype GB3 sequences from Kenya from 2012 sorted to cluster B1 with 90% bootstrap value. Cluster B9, the largest group in the phylogenetic tree with 89% bootstrap value, contained mostly genotype BA sequences from different countries, including the USA, Netherlands, Belgium, Peru, Vietnam, Kenya, Italy, Germany and a large number of sequences from China from 2002 to 2014. Like the Chinese HRSVA sequences, Chinese HRSVB sequences were in phylogenetic clusters populated by sequences from China as well as the other countries (Fig. 3 and Supplementary table S4b).

The phylogenetic analyses were also conducted using the maximum likelihood method. Phylogenetic trees generated by maximum likelihood method (Supplementary Figures S1 and S2) had the same cluster designations.

Pairwise-distance calculations of the F sequences. To determine the sequence variability of the F genes from samples collected in China or other countries, the p-distances of the sequences in the nucleotide and deduced amino acid levels were calculated. Overall, nucleotide and amino acid p-distances of the F sequences within the HRSVA or HRSVB subgroup from different countries were much smaller than those between the 2 subgroups within the same country (Table 2), indicating that the sequences were more similar within a subgroup than between subgroups. The nucleotide and amino acid p-distances of F sequences from China within or between the HRSVA or HRSVB subgroups were similar to those values for other countries. The nucleotide p-distances were usually ≤0.03 or ≤0.02 within the HRSVA or HRSVB subgroup, respectively, whereas the amino acid p-distances were usually ≤0.01 or ≤0.007 within the HRSVA or HRSVB subgroup, respectively. In contrast, the nucleotide and amino acid p-distances between the HRSVA and HRSVB F sequences from each of the source countries were in the range of 0.20–0.211 and 0.093–0.104, respectively. Furthermore, the nucleotide p-distance

Figure 1. Geographic distribution of 330 HRSV F gene sequences in China from 2003 to 2014. The pie map of the number of China HRSV subgroup A (red) and B (green) sequences was generated using ArcGis software (version 10.2). Phylogenetic clusters of HRSVA and HRSVB are shown in Figs 2 and 3.
between each cluster in a HRSVA or HRSVB phylogenetic tree was in the range of 0.02–0.06 or 0.01–0.03, respectively (Supplementary Tables S5a and S5b).

Of interest, F sequences of HRSV A appeared to be slightly more variable than those of HRSVB at both the nucleotide and amino acid levels (Table 2). When the amino acid sequences of the F protein from a country were

Figure 2. Phylogenetic trees of representative HRSVA F gene sequences from worldwide samples (a) and Chinese samples (b) from 1956 to 2014. Phylogenetic trees were generated using the neighbor joining method. Chinese sequences are denoted in red. In Panel b, the number within the parentheses behind the name of each representative sequence indicated the total number of sequences identical or similar (nucleotide difference less than 2) to that representative sequence.
compared to those from another country, there was usually over 98% or 99% identity for HRSVA or HRSVB sequences, respectively (Supplementary Table S5c and d). HRSV F sequences from China and other countries were highly conserved at both the nucleotide and amino acid levels.

Figure 3. Phylogenetic trees of representative HRSVB F gene sequences from worldwide samples (a) and Chinese samples (b) from 1962 to 2014. Phylogenetic trees were generated using the neighbor joining method. Chinese sequences are denoted in red. In Panel b, the number within the parentheses behind the name of each representative sequence indicated the total number of sequences identical or similar (nucleotide difference less than 2) to that representative sequence.
Sequence analysis of the neutralizing epitopes. The F protein harbors epitopes targeted by RSV-neutralizing antibodies. To analyze the sequence variation due to natural polymorphisms at the neutralizing epitopes of Chinese HRSV F protein sequences in comparison with those from other countries, all HRSV A (216 from China and 770 from other countries) and HRSVB (114 from China and 380 from other countries) F protein sequences were aligned with the sequences of the reference strains Long and CH18537, respectively.

All of the 216 Chinese HRSV A F sequences were 100% conserved at antigenic site Ø first domain (aa 62–69), and antigenic site II (aa 255–275), whereas 1 out of the 216 Chinese HRSV A F sequences had a substitution (L203F) at antigenic site Ø second domain (aa 196–210) compared to the reference sequence of Long (Supplementary Table S6). At antigenic site I (aa 380–400), V384I/T substitutions were observed in 947 (96%) HRSV A sequences from China and other 18 countries collected during the past 40 years. Substitutions V384I/T were only found in HRSV A sequences from Chongqing city in the Xinan region of China from 2011. Most of the other substitutions were less common. Substitution N380S was observed in 4 sequences collected in 2008 from Guangdong province in the Huanan region of China. Substitutions L381F, I395V and S436Y were each observed in 1 sequence from China.

For HRSVB F sequences, all Chinese sequences were 100% conserved at antigenic sites I, IV, V and VI (Supplementary Table S7). A number of HRSVB F sequence variations were identified at antigenic site Ø, e.g. 8 sequences from China (3 sequences of the SAB4 genotype from Beijing), Germany, Kenya, the UK and the USA had K65Q/T, 492 (~100%) sequences from different countries (including China) harbored the substitution R202Q, and 61 sequences from China and the USA carried Q209K/R. For antigenic site II (aa 255–275), 1 Chinese sequence from Beijing was found to have S259A, while 1 sequence from the USA had S255G. Overall, the sequences at the antigen site II of the F protein from HRSV A and HRSVB samples collected globally, including those from China, were highly conserved.

Over 95% of sequences had substitutions at a number of amino acid positions located outside of the antigenic sites: amino acid positions 8, 20, 101, 124, 213 and 515 in HRSV A (Supplementary Table S6), and positions 17, 152, 185 and 202 in HRSVB (Supplementary Table S7). Substitution R213S was detected in 981 (99%) HRSV A sequences from 17 countries from 1961–2014, including all (216) HRSV A sequences from China.

Sequence analysis of the cytotoxic T lymphocyte epitopes. Virus-specific CTLs play an important role in the clearance of HRSV infection. To date, 4 CTL epitopes have been identified in the F protein: HLA-A*01 (aa 109–118), HLA-B*57 (aa 106–114), HLA-Cw*12 (aa 551–559) and HLA-A*0201 (aa 33–41, 214–222, 273–281 and 559–567).

In this study, no substitutions were detected at aa 106, 108–118 and 551–559 in HRSV sequences from China. Two Chinese sequences had a substitution at aa 107 (A107T) (Supplementary Table S6). For HRSVB F protein sequences, aa 108–111, 116, 118, and 555–558 were 100% conserved worldwide (Supplementary Table S7).

### Table 2. Nucleotide and amino acid p-distances within/between HRSVA and HRSVB F sequences.

| Country | p-distance | Within HRSVA Nucleotide | Amino acid | Within HRSVB Nucleotide | Amino acid | Between HRSVA and HRSVB Nucleotide | Amino acid |
|---------|-------------|-------------------------|------------|-------------------------|------------|-------------------------------------|------------|
| AR      | 0.001       | 0.001                   | 0.005      | 0.005                   | 0.005      | 0.207                               | 0.103      |
| AUS     | 0.017       | 0.007                   | 0.007      | 0.005                   | 0.005      | 0.202                               | 0.103      |
| BE      | 0.023       | 0.011                   | 0.004      | 0.003                   | 0.003      | 0.207                               | 0.101      |
| CHN     | 0.010       | 0.005                   | 0.013      | 0.007                   | 0.007      | 0.211                               | 0.102      |
| GER     | 0.010       | 0.005                   | 0.017      | 0.007                   | 0.007      | 0.211                               | 0.102      |
| IN      | 0.023       | 0.011                   | 0.004      | 0.003                   | 0.003      | 0.207                               | 0.101      |
| ITA     | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.101      |
| KSA     | 0.002       | 0.005                   | 0.013      | 0.006                   | 0.006      | 0.204                               | 0.103      |
| MEX     | 0.023       | 0.011                   | 0.02       | 0.01                    | 0.01       | 0.2                                  | 0.098      |
| NL      | 0.010       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| PE      | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| PHI     | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| RSA     | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| SK      | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| SG      | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| UK      | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| USA     | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
| VN      | 0.002       | 0.005                   | 0.007      | 0.003                   | 0.003      | 0.207                               | 0.098      |
Table S7). Substitutions N554K/S/T were observed in 5 Chinese HRSVB sequences, and 1 HRSVB sequence from Beijing China had the L559I substitution. HRSV A N276S substitution was observed in 84.3% (182/216) Chinese sequences and 57.3% (441/770) sequences from other countries in 2007–2014, whereas only 4 HRSVB sequences from China (n = 1) and the USA (n = 3) collected in 2013–2014 had a substitution at this amino acid position (S276N). One Chinese HRSVB sequence contained I221V.

Overall, CTL-specific epitopes in HRSV sequences from all countries, including China, were well conserved. The substitutions, if any, in the sequence of the epitopes appeared to vary by positions depending on the countries of origin of the samples, but some substitutions (e.g. N276S in HRSV A) were found across different countries.

Sequence analysis of the N/O-glycosylation sites of Chinese HRSV F sequences. N- or O-glycosylation can modify the biological activity of a protein. In this study, 6 N-glycosylation sites (aa 27, 70, 116, 120, 126 and 500) were predicted in the F protein of the HRSV reference strains of Long and CH18537 (Table 3). All Chinese F protein sequences had the 6 predicted N-glycosylation sites, with the exception of a single HRSV A sequence from Guangdong which had a mutation at aa 122 (T122P) leading to the change of the amino acid sequence from NNTK to NNPK and the loss of the predicted N-glycosylation site at aa position 120.

In contrast to the prediction of N-glycosylation sites in almost all HRSV sequences, O-glycosylation sites were predicted in 42 HRSV sequences by the NetOGlyc 4.0 method: 6 O-glycosylation sites (aa 99, 100, 101, 118, 128 and 244) were predicted in 20 Chinese HRSVB F sequences and 8 O-glycosylation sites in 20 Chinese HRSVA F sequences. The more common amino acid positions with predicted O-glycosylation sites in HRSV A or HRSVB F sequences included positions 99, 118 and 128. The O-glycosylation site at aa 128 was predicted in 19 HRSVB sequences and 2 HRSV A sequences from the Xinan, Zhongnan and Huabei regions in China. O-glycosylation at these predicted sites needs to be investigated, as O-linked glycan have not been reported on a HRSV F protein previously.

Selection pressure site prediction. The selection pressure on Chinese HRSV was estimated using the dN/dS ratio. The mean dN/dS ratios for Chinese HRSVA and HRSVB were 0.092 and 0.098, respectively, while the mean dN/dS ratios for HRSVA and HRSVB from other countries were 0.106 and 0.120, respectively (Table 4). In this analysis, dN/dS ratios > 1 were considered as evidence of positive selection. More negative selection sites than positive selection sites were predicted in HRSV sequences from China and other countries. No positive selective

### Table 3. Predicted N/O-glycosylation sites in Chinese HRSV F sequences.

| Site | Sequence name or accession numbers | Amino acid | Subgroup |
|------|------------------------------------|------------|----------|
| NITE | All Chinese sequences              | 27         | A/B      |
| NGTD | All Chinese sequences              | 70         | A/B      |
| NYTL | All Chinese sequences              | 116        | A/B      |
| NNTK | All Chinese sequences except Guangzhou10–01(HRSVA) | 120       | A/B      |
| NVTG | All Chinese sequences              | 126        | A/B      |
| NQSL | All Chinese sequences              | 500        | A/B      |

**N-glycosylation**

| Site | Sequence name or accession numbers | Amino acid | Subgroup |
|------|------------------------------------|------------|----------|
| 99S  | BJ04–34, BJ09–105, KP119745, GZ11–161, BJ04–23, JX682745, BJ04–44, GZ11–21, JX682724, GZ11–18, KP119748 | 99          | A        |
| 100T | BJ04–34, BJ09–105, BJ04–23, KP218910, BJ04–32, GZ11–18 | 100         | A        |
| 101S | BJ10–2, JX682716, BJ04–01, JX682745 | 101         | A        |
| 118T | BJ04–34, BJ09–105, KP119745, GZ11–16, BJ04–23, KP218910, KP119746, BJ10–2, JX682716, BJ04–01, GZ11–21, JX682724, GZ11–18, KP119748 | 118         | A        |
| 128T | GZ11–16, JX682724 | 128         | A        |
| 244T | GZ10–01, JX682718 | 244         | A        |
| 100T | GG09–1 | 100         | B        |
| 102S | GG09–1 | 102         | B        |
| 105S | BJ09–43 | 105         | B        |
| 115T | CC14–49 | 115         | B        |
| 118T | CC14–49 | 118         | B        |
| 122T | GZ10–05, GZ10–04, BJ09–112, HN14–16, BJ09–21, BJ10–20 | 122         | B        |
| 128S | GZ10–05, JX682801, BJ09–75, GZ10–09, JX682807, BJ09–64, JX682820, BJ09–110, JX682808, GZ10–04, HN12–30, BJ10–16, BJ09–112, HN14–16, JX682803, BJ09–21, BJ09–50, BJ09–65, BJ10–20 | 128         | B        |
| 130S | HN12–30 | 130         | B        |
sites were detected by the single likelihood ancestor counting (SLAC) method in all HRSV F gene sequences from China or other countries, whereas a total of 3 positive selective sites (aa 125, 152, 1574) in Chinese sequences and a total of 4 positive selective sites (aa 15, 152, 384, 573) in sequences from other countries were predicted by the fixed effects likelihood (FEL) and the internal fixed effects likelihood (IFEL) methods.

Discussion

Little is known about the sequence characteristics and genetic diversity of Chinese HRSV F gene. In this study, 330 Chinese HRSV F gene sequences from different regions in China were analyzed together with 1150 HRSV F gene sequences from 18 other countries by phylogenetic analysis and other sequence analyses. The present study provides important information regarding the genetic diversity and sequence characteristics of Chinese HRSV F sequences from 2003–2014. Results presented in this study provide information for the development of vaccines, neutralizing antibodies and other therapies for HRSV infection.

The sequence of the HRSV G gene is highly variable. Due to the genetic diversity in the G gene, sequence encoding the second hypervariable region in the C-terminal of the G protein has been used for genotyping of HRSV. In contrast, the sequence of the HRSV F gene is highly conserved. Most of the molecular epidemiology studies of HRSV were conducted using the sequences of the G gene. However, there is increased interest in the molecular epidemiology of the F protein in recent years as F protein is a target of neutralizing antibodies and vaccine development. In this study, phylogenetic analysis of ~1500 HRSV F sequences from samples collected from the extended period of 1956–2014 worldwide, including 330 sequences from China from 2003–2014, identified 11 and 9 clusters with the sequences of the HRSVA and HRSVB subgroups, respectively. Of interest, F sequences from different genotypes (as determined based on the G gene sequences) within a HRSV subgroup could be found in the same clusters in phylogenetic trees generated based on F gene sequences, e.g. cluster A11 of HRSVA contained sequences from HRSVA genotypes NA1, NA3 and ON1.

Our p-distance calculations showed that there was a high level of sequence identity between the F sequences from China and other countries. In addition, the variability of the F sequences from HRSVA was slightly higher than that from HRSVB samples collected from China as well as many other countries, which was consistent with observations reported previously.

Table 4. Predicted selection pressure sites in HRSV F sequences. SLAC = single likelihood ancestor counting method, FEL = fixed effects likelihood method, IFEL = internal fixed effects likelihood method.

| Sequence Origin | HRSV subgroup | Mean dN/dS | No. of positive selective sites (aa position, p-value) | No. of negative selective sites | Significance p-value |
|-----------------|---------------|-----------|--------------------------------------------------------|--------------------------------|---------------------|
| China           | A             | 0.092     | 0 0 1 (574, 0.049)                                     | 31 92 25                      | 0.05                |
|                 | B             | 0.098     | 0 1 (125, 0.035)                                      | 21 54 8                       | 0.05                |
| Other countries | A             | 0.106     | 0 0 2 (125, 0.035; 384, 0.045)                         | 159 234 148                   | 0.05                |
|                 | B             | 0.120     | 0 2 (15, 0.036; 573, 0.035)                            | 0 70 141 284                  | 0.05                |

All Chinese HRSVA sequences were highly conserved at antigenic site Ø (aa 62–69 and 196–210), but 3 Chinese HRSVB sequences classified as the SAB4 genotype from Beijing had the K65Q substitution and sorted to a separate group in the B7 cluster of the phylogenetic tree, suggesting that K65Q could be a genotype specific amino acid change. Other HRSVB substitutions such as R202Q and Q209K/R were also detected at antigenic site Ø. Antigenic site I is located in the middle cluster of the cysteine-rich region of the F1 chain. The F1 subunit is essential for membrane fusion. Antibodies binding to antigenic site I have marginal effect in virus neutralization. Similar to antigenic site I, antigenic sites IV, V, and VI are also located near the C-terminal end of the cysteine-rich region and not far from the heptad repeat adjacent to the membrane of the F1 chain. During the fusion process, neutralizing antibodies binding to both sides of the cysteine cluster would inhibit conformational changes of the F1 chain. Previous studies have shown that substitutions aa 258, 272 and 275 of the F protein conferred resistance to palivizumab in vitro or in vivo. Only 1 Chinese HRSVB sequence has the substitution of S259A at antigenic site II. The impact of the S259A substitution on viral pathogenesis remains to be determined.

The CTL epitopes were well conserved in HRSV sequences from China and other countries. However, N276S substitution was commonly detected in the CTL epitopes of HRSV F sequences from China as well as many other countries. In our study, 84.3% (182/216) Chinese HRSVA sequences carried the N276S substitution. The percentage of Chinese HRSVA strains with the N276S substitution was found to be increasing after 2014. Although aa N276 is next to the palivizumab binding site (aa 262–275), the N276S substitution has been proved to be a natural polymorphism and does not impact the susceptibility of HRSV to palivizumab.

N-glycans on viral glycoproteins are important structural components that could affect the folding, transport, activity, stability and immunological properties of the viral glycoproteins. It has been shown that the loss of the N-glycan in HIV gp120 could affect the sensitivity of HIV to neutralizing antibodies and modulate the structure, stability or accessibility of viral epitopes in the CD4 binding site and co-receptor binding region of HIV. There are generally 5 or 6 potential N-linked glycosylation sites in HRSV F protein depending on the viral strains.
sequence conservation at its binding site. Only a small number of substitutions associated with resistance to antigenic site II of the HRSV F protein, and is cross-reactive with the F protein of HRSV A and HRSVB due to the HRSV infection in high-risk infants in the USA and other countries. Palivizumab binds to the highly conserved humanized monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by Disease Control and Prevention (NIVDC) of the Center for Disease Control and Prevention (CDC) in China and nasopharyngeal precipitates was obtained from adult patients and parents or guardians of pediatric patients. Written informed consent for the use of their aspirates) were collected from patients with respiratory infections. In this study, we found that the palivizumab binding site in the F protein sequences from all of the Chinese HRSV F protein were < 1 and demonstrated the hemagglutinin amino acid substitutions were the result of random genetic drift rather than accumulated mutations. In this study, we found that the mean dN/dS ratios of the F genes for both HRSVA and HRSVB strains in China and other countries had a value < 1, suggesting that the amino acid substitutions in F protein of HRSV were also the results from random genetic drift. In addition, it was reported that most HRSV genes, with the exception of the G gene, have negative selection or neutrally evolving sites. Consistent with this finding, we identified only 3 positive selection sites for HRSVA (aa 152, 384 and 574) and 4 positive selection sites for HRSVB (aa 15, 125, 201 and 573) in ~1500 HRSV F sequences collected worldwide. Positive selection sites at aa 15 and aa 125 are located in the F2 subunit and pep27, respectively, whereas the other 5 positive selection sites are all located in the F1 subunit. Amino acid 384 is located in antigenic site I, and we found that the substitutions V384I/T were present in 96% of HRSVA sequences collected all over the world. Amino acid 125 is located in pep27. Recently, it has been shown that the binding to a pep27-containing peptide (F 101–121) was higher with sera from HRSV-infected infants with neutralizing antibodies than infants without neutralizing antibodies, indicating the presence of missed F0 conformation. Consistent with the results from previous studies, substitutions L125S/P were found in 8% HRSVB sequences in our study. The potential effect of substitutions at these positive selection sites on the pathogenesis of HRSV remains to be determined.

There are currently no specific antiviral treatments or vaccines approved for HRSV infection. Palivizumab is a humanized monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by HRSV infection in high-risk infants in the USA and other countries. Palivizumab binds to the highly conserved antigenic site of the HRSV F protein, and is cross-reactive with the F protein of HRSVA and HRSVB due to the sequence conservation at its binding site. Only a small number of substitutions associated with resistance to palivizumab have been identified in vitro or in vivo; these substitutions were at aa 262, 268, 272 and 275 of the F protein. In this study, we found that the palivizumab binding site in the F protein sequences from all of the 330 Chinese HRSV samples was 100% conserved, and 100% identical to the corresponding site found in the F protein sequences of prototypic HRSVA and HRSVB strains, both of which are susceptible to the neutralization by palivizumab. No mutations were found at the amino acid positions which are known to confer resistance to palivizumab. Taken together, these results predict that the endemic Chinese HRSV strains would be susceptible to the neutralization effect of palivizumab in the clinical setting. The susceptibility of Chinese HRSV strains to neutralization by palivizumab should be confirmed in vitro and in vivo.

There are some limitations in the present study. This study is a retrospective study and the source of available sequences was limited by the number of samples collected previously. Most of the sequences were downloaded from GenBank without the information of DNA sequencing methods, which might have different detection limits. In addition, while sequences of most samples were amplified directly from clinical specimens, some were amplified from samples previously isolated, which might have some impact on the sequencing results. Different countries had different number of sequences and the collection dates of the samples were not successive. Furthermore, samples were from 6 representative regions of China instead of from all over China, and the number of samples from each region was different.

In conclusion, this study investigated the sequence diversity of the HRSV F gene from 330 samples collected in China from 2003–2014. The F gene sequence was highly conserved in HRSV strains from China as well as those from 18 other countries. The high level of sequence conservation in the HRSV F sequences worldwide supports the F protein as a target for vaccine development and antiviral therapy. The evolution of the F gene of HRSV strains from China and the rest of the world should be monitored continuously for genetic diversity and changes in functional and antigenic properties.

Methods

Ethics statement. This study did not involve human experimentation and only nasopharyngeal precipitates (aspirates) were collected from patients with respiratory infections. Written informed consent for the use of their nasopharyngeal precipitates was obtained from adult patients and parents or guardians of pediatric patients. This study was approved by the second session of the Ethics Review Committee of the National Institute for Viral Disease Control and Prevention (NIVDC) of the Center for Disease Control and Prevention (CDC) in China and the methods were performed in accordance with the approved guidelines.

Sample collection. 181 representative Chinese HRSV samples were selected from over 700 HRSV-positive samples for the determination of the full-length CDS of the F gene based on HRSV subgroup, genotype (designation based on the sequence of the G gene), genetic diversity (different clustering within a genotype in phylogenetic analysis using the sequences of the G gene), geographical region, and year of collection. The 181 samples included 91 HRSVA samples (40 isolates and 51 clinical specimens) and 90 HRSVB samples (18 isolates and 72 clinical specimens) from 5 representative geographic regions of China (Dongbei, Huabei, Huadong, Zhongnan and Xibei regions) between 2004 and 2014 (Supplementary Table S1). The genotypes of the samples included GA2, GA5, NA1, NA3, NA4, ON1, BA3, BA4, BA6, BA9, BA10, BA11, CB1 and SAB4 (genotypes
determined based on the sequence of the second hypervariable region of the G gene as described in our previous studies7,10. The 181 Chinese F gene sequences were submitted to GenBank with the accession numbers of KY296617–KY296797, as shown in Supplementary Table S1.

Viral RNA extraction. Viral RNA was extracted from clinical specimens or cultured isolates identified as positive of HRSV using the QIAamp RNA mini kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions.

Nucleotide amplification and sequencing. The second hypervariable region of the G gene of each HRSV sample was first sequenced and then analyzed in phylogenetic analysis to determine its genotype as described previously7,10. Depending on the designated genotypes and other criteria as described in “Sample collection” above, 181 HRSV samples were selected for F gene sequencing.

PCR amplifications of the full-length CDS of the F gene (in 3 separate fragments) were performed using the One Step RT-PCR kit (TaKaRa Biotechnology, Dalian, China). The PCR and sequencing primers are shown in Supplementary Table S8. Reaction mix contained 5 ul RNA, 12.5 ul reaction buffer, 1 ul One Step Enzyme Mix and 0.4 uM of a forward and reverse primer. The amplification was conducted at 50 °C for 30 min for reverse transcription, 94 °C for 2 min for denaturation, and with 40 cycles of 94 °C for 30 sec, 50 °C for 30 sec, 72 °C for 60 sec (105 sec for HRSV F2 fragment) for amplification, followed by a final extension at 72 °C for 10 min. The PCR products were all purified using a QIAQuick Gel Extraction Kit (Qiagen) and sequenced using an ABI Prism 3710 × 1 DNA Analyzer. The sequences were the edited using Sequencher software version 5.0 (Gene Codes, Ann Arbor, MI, USA).

Phylogenetic, p-distance and amino acid variation analyses. Phylogenetic trees were generated using the software MEGA 5.0 with the neighbor joining method with Kimura 2-parameter model or maximum likelihood method with GTR + G + I model. Evaluation of the reliability of phylogenetic inference was estimated using the bootstrap method with 1000 replicates with a cut-off value of usually >7014. In this study, a cluster was defined as a group of sequences within a distinct branch in the phylogenetic tree, and the higher bootstrap, the higher reliability. Sequences were aligned using ClustalW in the MEGA 5.0 software and the pairwise distance (p-distance) of nucleotide and deduced amino acid among sequences were also calculated using MEGA 5.015. The N- and O-glycosylation sites were predicted using the NetN Gly 1.0 and NetO Gly 4.0 server16,17, respectively. Selection pressure was determined on the Datamonkey website (http://www.datamonkey.org/) by estimating the ratio of non-synonymous (dn) and synonymous (ds) substitution per site based on the SLAC, FEL, and IFEL methods with a significance level of 0.05. The reference strains used in this study were Long (GenBank accession number JX198112) and CH18537 (GenBank accession number JX198143).

Nucleotide sequence accession numbers and HRSV sequences downloaded from GenBank. All full-length HRSV F gene sequences that were available in GenBank as of October 2016, including 149 sequences from Xinan, Zhongnan, Huabei and Huadong regions of China and 1150 sequences from 18 other countries from Asia, Europe, North America, South America, Australia, and Africa (details shown in Supplementary Tables S2 and S3) were downloaded for analysis together with the 181 full-length F gene sequences that were generated from samples collected in this study.

References
1. Saxena, S. et al. Clinical characterization of influenza A and human respiratory syncytial virus among patients with influenza like illness. J Med Virol 89, 49–54 (2017).
2. Kumar, P. et al. Etiology of Acute Respiratory Infections in Infants: A Prospective Birth Cohort Study. Pediatr Infect Dis J (2016).
3. Collins, P. L. & Graham, B. S. Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. Journal of Virology 82, 2040–2055 (2007).
4. Levine, S., Klaiber-Franco, R. & Paradiso, P. R. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 68(9), 2521–2524 (1987).
5. McLellan, J. S., Ray, W. C. & Peeples, M. E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372, 83–104 (2013).
6. Sullender, W. M. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 13, 1–15, table of contents (2000).
7. Song, J. et al. Emergence of ON1 genotype of human respiratory syncytial virus subgroup A in China between 2011 and 2015. Scientific Reports 7 (2017).
8. Duvvuri, V. R. et al. Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. Scientific Reports 5 (2015).
9. Gimferrer, L. et al. Circulation of a novel human respiratory syncytial virus Group B genotype during the 2014–2015 season in Catalonia (Spain). Clinical Microbiology and Infection 22, 97.e95–97.e98 (2016).
10. Song, J. et al. Emergence of B9 genotype of human respiratory syncytial virus subgroup B in China from 2006 to 2014. Scientific Reports 7 (2017).
11. Abrego, L. E. et al. Genetic variability of human respiratory syncytial virus subgroup B in Panama reveals a novel genotype BA14. Journal of Medical Virology 89, 1734–1742 (2017).
12. Cui, G. et al. Genetic variation in attachment glycoprotein genes of human respiratory syncytial virus subgroups A and B in children in recent five consecutive years. PLoS One 8, e75020 (2013).
13. Zheng, Y. et al. Prevaling genotype distribution and characteristics of human respiratory syncytial virus in northeastern China. Journal of Medical Virology 89, 222–233 (2017).
14. Aukormkitti, V. et al. Molecular characterization of human respiratory syncytial virus, 2010–2011: identification of genotype ON1 and a new subgroup B genotype in Thailand. Archives of virology. 159, 499–507 (2014).
15. Varga, S. M. et al. Sequencing and Analysis of Globally Obtained Human Respiratory Syncytial Virus A and B Genomes. Plos One 10, e0120998 (2015).
16. Collins, P. L. & Mottet, G. Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 72(Pt 12), 3095–3101 (1991).
17. Gonzalez-Reyes, L. et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. *Proceedings of the National Academy of Sciences* **98**, 9859–9864 (2001).
18. Graham, B. S., Modjarrad, K. & McLellan, J. S. Novel antigens for RSV vaccines. *Current Opinion in Immunology* **30**, 30–38 (2015).
19. Zimmer, G., Trotz, I. & Herrler, G. N-Glycans of F Protein Differentially Affect Fusion Activity of Human Respiratory Syncytial Virus. *Journal of Virology* **75**, 4744–4751 (2001).
20. Tregoning, J. S. et al. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. *PloS One* **12**, e0175792 (2017).
21. McLellan, J. S. et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. *Science* **340**, 1113–1117 (2013).
22. Connolly, S. A., Leser, G. P., Yin, H. S., Jardetzky, T. S. & Lamb, R. A. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. *Proceedings of the National Academy of Sciences* **103**, 17903–17908 (2006).
23. McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. *Journal of Virology* **85**, 7788–7796 (2011).
24. Brandenburg, A. H. et al. HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. *J Virol* **74**, 10240–10244 (2000).
25. Rock, M. T. & Crowe, J. E. Jr. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. *Immunology* **108**, 474–480 (2003).
26. Tripp, R. et al. Molecular Epidemiology and Phylogenetics of the Human Respiratory Syncytial Virus Fusion Protein in Northern Taiwan. *PloS ONE* **8**, e64012 (2013).
27. Wu, Y. et al. Immunoprotective activity of HLA-A2 CTL Peptides Derived from Respiratory Syncytial Virus Fusion Protein in HLA-A2 Transgenic Mouse. *PloS ONE* **6**, e25590 (2011).
28. Swanson, K. A. et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. *Proceedings of the National Academy of Sciences* **108**, 9619–9624 (2011).
29. Varga, S. M. et al. Gene Sequence Variability of the Three Surface Proteins of Human Respiratory Syncytial Virus (HRSV) in Texas. *PloS ONE* **9**, e90786 (2014).
30. Lopez, J. A. et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. *J Virol* **72**, 6922–6928 (1998).
31. Crowe, J. E. et al. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. *Virology* **252**, 373–375 (1998).
32. Lopez, J. A. et al. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. *J Gen Virol* **74**(Pt 12), 2567–2577 (1993).
33. Arbizu, J. et al. Antigenicity of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. *J Gen Virol* **73**(Pt 9), 2225–2394 (1992).
34. Zhu, Q. et al. Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab. *Journal of Infectious Diseases* **203**, 674–682 (2011).
35. Zhu, Q. et al. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. *J Infect Dis* **205**, 635–638 (2012).
36. Chen, X. et al. Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China. *Scientific Reports* **8** (2018).
37. Xia, Q. et al. Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China. *Arch Virol* **159**, 1089–1098 (2014).
38. Townsley, S. et al. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. *Journal of Virology* **90**, 829–841 (2016).
39. Zimmer, G., Conzelmann, K. K. & Herrler, G. Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture. *Journal of Virology* **76**, 9218–9224 (2002).
40. Lin, B. et al. Genetic Characterization of the Hemagglutinin Genes of Wild-Type Measles Virus Cirulating in China, 1993–2009. *PLoS ONE* **8**, e73374 (2013).
41. Leung, F. C. C. et al. Genetic Variability among Complete Human Respiratory Syncytial Virus Subgroup A Genomes: Bridging Molecular Evolutionary Dynamics and Epidemiology. *PLoS ONE* **7**, e41439 (2012).
42. Wilson, P. C. et al. Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. *PLOS Pathogens* **12**, e1005554 (2016).
43. Gaunt, E. R. et al. Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus. *PLoS One* **6**, e17427 (2011).
44. Zakharkh, A. & Li, W. H. Estimation of confidence in phylogeny: the complete-and-partial bootstrap technique. *Mol Phylogenet Evol* **4**, 44–63 (1995).
45. Tamura, K. et al. MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* **28**, 2731–2739 (2011).
46. Steenoft, C. et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. *The EMBO Journal* **32**, 1478–1488 (2013).
47. Kimura, H. et al. Molecular evolution of the fusion protein (F) gene in human respiratory syncytial virus subgroup B. *Infect Genet Evol* **52**, 1–9 (2017).

**Acknowledgements**
We thank the staffs in the sentinel hospitals of Jilin, Beijing, Hebei, Shandong, Shanghai, Guangdong, Hunan, Gansu and Shaanxi provinces. This work was supported by the National Natural Science Foundation of China (project no. 81772195), the Key Technologies R&D Program of National Ministry of Science (2018ZX10713002, 2017ZX10104001-002, 2018ZX10713001-003) and Non-clinical laboratory service agreement with AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd.

**Author Contributions**
W.B.X. and Y.Z. conceived and designed the study. J.H.S., H.L.W., A.L.C., S.L.Z., Y.Z.H., L.W.S., Z.F.Y., D.S.Y., P.B.Y. and H.Z. performed the specimen collection and experiments, J.H.S., Y.Z. and W.B.X. performed sequences and data analysis. J.H.S., T.I.N., Y.Z. and W.B.X. wrote and edited the main manuscript. J.H.S. prepared the tables and figures. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-35894-3.

Competing Interests: Teresa I. Ng is an employee of AbbVie and may hold stocks or stock options of AbbVie. AbbVie markets palivizumab (Synagis®) in countries outside the US. The other authors declare no competing interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018